Fresh Tracks Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.486 million compared to USD 0.132 million a year ago. Net loss was USD 6.02 million compared to USD 13.25 million a year ago. Basic loss per share from continuing operations was USD 2.07 compared to USD 7.15 a year ago.
For the nine months, revenue was USD 4.89 million compared to USD 0.3 million a year ago. Net loss was USD 16.58 million compared to USD 33.41 million a year ago. Basic loss per share from continuing operations was USD 6.05 compared to USD 21.19 a year ago.